Compare NetEase Inc (NTES) vs Novartis AG (NVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
NetEase Inc vs Novartis AG — how do they compare? NetEase Inc trades at $134.95 (market cap $86.14B), while Novartis AG trades at $153.88 (market cap $290.25B). The key difference: Novartis AG is far larger — about 3.4× NetEase Inc's market cap, and Novartis AG pays the higher dividend (3.17%). Which is the better fit depends on your goals.
| NTES | NVS | |
|---|---|---|
Market Cap | $86.14B | $290.25B |
Sector | Media | Health |
52-Week High | $159.34 | $168.62 |
52-Week Low | $109.26 | $113.50 |
Enterprise Value | $62.61B | $330.27B |
Dividend Yield | 2.25% | 3.17% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NetEase (NTES) trades at $129.57, down 1.31% over the past day, with a bullish technical outlook supported by moving averages. The company reported strong Q1 2026 earnings of $2.53 EPS, beating expectations, and maintains robust profitability with a 29.84% net income margin. Recent news highlights international expansion and a Zacks Strong Buy upgrade, while the stock offers a dividend with the next payment scheduled for June 18, 2026.
The outlook for NTES is positive, driven by earnings growth, cash flow strength, and analyst optimism, with a 34.66% upside to price targets. Key risks include China market volatility and competitive pressures in gaming. The stock presents a value opportunity with a P/E of 17.26, but investors should monitor geopolitical and regulatory developments.
Novartis (NVS) trades at $153.87, showing minimal daily movement with a slight 0.07% gain. The stock exhibits bearish technical signals from moving averages despite a neutral oscillator reading. Fundamentally, the company reported strong Q2 2026 earnings that beat expectations, with revenue of $56.67 billion in 2025 and robust profitability margins, including a net income margin of 23.92%. Recent news highlights successful drug launches offsetting generic competition pressures.
The outlook remains cautiously optimistic as new medicines drive growth, but risks include patent expirations and pipeline trial results. Analyst sentiment is mixed with 68% hold ratings, reflecting balanced views on execution versus competitive threats. Investment appeal hinges on sustained drug innovation and margin stability amid industry headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About NetEase Inc
NetEase, which started on an internet portal service in 1997, is a leading online services provider in China. Its key services include online/mobile games, cloud music, media, advertising, email, live streaming, online education, and e-commerce. The company develops and operates some of the China's most popular PC client and mobile games, and it partners with global leading game developers, such as Blizzard Entertainment and Mojang (a Microsoft subsidiary).
Read more on NTES →About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →
